Some drug classes have been amalgamated from these three principles to meet practical needs. The class of [[nonsteroidal anti-inflammatory drugs]] (NSAIDs) is one such example. Strictly speaking, and also historically, the wider class of anti-inflammatory drugs also comprises of [[Corticosteroid|''steroidal'' anti-inflammatory drugs]]. These drugs were in fact the predominant anti-inflammatories during the decade leading up to the introduction of the term "nonsteroidal anti-inflammatory drugs." Because of the disastrous reputation that the corticosteroids had got in the 1950s, the new term, which offered to signal that an anti-inflammatory drug was not a steroid, rapidly gained currency.<ref name="Buer_2014">{{cite journal | vauthors = Buer JK | title = Origins and impact of the term 'NSAID' | journal = Inflammopharmacology | volume = 22 | issue = 5 | pages = 263–7 | date = Oct 2014 | pmid = 25064056 | doi = 10.1007/s10787-014-0211-2 | hdl = 10852/45403 | s2cid = 16777111 | hdl-access = free }}</ref> The drug class of "nonsteroidal anti-inflammatory drugs" (NSAIDs) is thus composed by one element ("anti-inflammatory") that designates the mechanism of action, and one element ("nonsteroidal") that separates it from other drugs with that same mechanism of action. Similarly, one might argue that the class of disease-modifying anti-rheumatic drugs (DMARD) is composed by one element ("disease-modifying") that albeit vaguely designates a mechanism of action, and one element ("anti-rheumatic drug") that indicates its therapeutic use.
